Peptides for Liver Cancer Support: Targeted Therapies

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based therapies are emerging as a promising strategy for liver cancer support, offering direct tumor targeting, immune modulation, and enhanced drug delivery. These novel interventions aim to improve patient outcomes and provide more targeted and less toxic treatment options.

Peptides for Liver Cancer Support: Targeted Therapies and Immunomodulation

Liver cancer, particularly hepatocellular carcinoma (HCC), remains a formidable challenge in oncology, often associated with poor prognosis and limited treatment options. While conventional therapies like surgery, chemotherapy, and targeted drugs exist, their efficacy can be limited by side effects and resistance. Peptides, with their high specificity, low toxicity, and diverse biological activities, are emerging as a promising avenue for liver cancer support, offering novel strategies for direct tumor targeting, immune modulation, and synergistic treatment.

Peptide-Based Strategies in Liver Cancer Management

Peptides are being developed to attack liver cancer cells directly, enhance the body's immune response against tumors, and improve the effectiveness of existing treatments.

1. Direct Anticancer Peptides (ACPs)

• Inducing Apoptosis: Some peptides, such as those derived from Laminaria japonica (LJP-1), have demonstrated strong inhibitory effects on liver cancer growth by inducing apoptosis (programmed cell death) in tumor cells [6].
• Triggering Cell Death: Hybrid peptides like NTP-217 have been shown to trigger reactive oxygen species (ROS)-mediated rapid cell death in liver cancer cells, offering a potent direct cytotoxic effect [12].
• Inhibiting Proliferation Pathways: Specific peptides can inhibit key signaling pathways that drive cancer cell proliferation. For example, peptides that target and inhibit the FGF19–FGFR4 pathway have been shown to reduce proliferation and tumor growth in HepG2 cells [13].
• Reducing Cell Viability and Migration: Hemp Bioactive Peptides (HP) have been observed to increase apoptosis and reduce both cell viability and migration in Hep3B human liver cancer cells, suggesting a role in preventing tumor spread [14].
• Venom-Derived Peptides: Bioactive peptides found in the venom of certain organisms, such as the Tv1 venom peptide, have shown antitumor effects in liver cancer models, highlighting nature's diverse arsenal against cancer [15].

2. Peptide-Based Immunotherapy and Vaccines

• Tumor-Specific Immune Response: Immunotherapy is a highly attractive strategy for HCC, aiming to induce tumor-specific immune reactions without causing widespread autoimmunity [7]. Peptide vaccines are designed to achieve this by presenting tumor-associated antigens to the immune system.
• Targeting Glypican-3 (GPC3): GPC3 is an oncofetal protein highly overexpressed in HCC, making it an excellent target for immunotherapy. Peptide vaccines targeting GPC3 have been developed and tested in clinical trials, aiming to stimulate an immune response against GPC3-positive liver cancer cells [10, 11].
• Therapeutic Peptide Vaccines: A therapeutic peptide vaccine targeting DNAJ-PKAc (FLC-Vac) has been investigated in a phase 1 clinical trial for fibrolamellar hepatocellular carcinoma (FLC). This vaccine, often combined with immune checkpoint inhibitors like nivolumab, aims to trigger the immune system to expand an “army” of trained T cells that can specifically recognize and eliminate cancer cells [8, 9].

3. Enhancing Drug Delivery and Efficacy

• Bi-Functional Peptides: These peptides can exploit the expression of tumor-penetrating peptide receptors, allowing for more targeted delivery of therapeutic agents directly to the tumor site, potentially increasing efficacy and reducing systemic toxicity [4].

Clinical Outlook and Practical Advice

The field of peptide therapeutics for liver cancer is rapidly advancing, offering innovative approaches that are more targeted and potentially less toxic than traditional treatments. These strategies hold promise for improving patient outcomes, especially in combination with existing therapies.

Practical Takeaway

If you or a loved one are facing a liver cancer diagnosis, it's crucial to discuss all available treatment options with your oncology team. While many peptide-based therapies are still in clinical trials or early development, staying informed about these advancements and exploring participation in relevant studies can provide access to cutting-edge treatments and contribute to the ongoing fight against liver cancer.

References

[1] Zhang, L., et al. (2019). Antimicrobial Peptides: Potential Application in Liver Cancer. Frontiers in Pharmacology, 10, 656. https://pmc.ncbi.nlm.nih.gov/articles/PMC6560174/
[2] ecancer.org. (2018). Scientists develop novel drug that could potentially treat liver cancer more effectively. https://ecancer.org/en/news/14517-scientists-develop-novel-drug-that-could-potentially-treat-liver-cancer-more-effectively
[3] OHC. (n.d.). New Drug (FFW) May Improve Liver Cancer Therapy. https://ohcare.com/new-drug-ffw-liver-cancer-therapy/
[4] Li, Y., et al. (2021). Bi-Functional Peptides as a New Therapeutic Tool for Liver Cancer. Frontiers in Oncology, 11, 8541685. https://pmc.ncbi.nlm.nih.gov/articles/PMC8541685/
[5] UCLA Health. (2026). UCLA researchers identify peptide that inhibits replication of hepatitis C. https://www.uclahealth.org/news/release/ucla-researchers-identify-peptide
[6] Li, Y., et al. (2021). Laminaria japonica Peptides Suppress Liver Cancer by Inducing Apoptosis and Inhibiting Angiogenesis. Marine Drugs, 20(11), 704. https://www.mdpi.com/1660-3397/20/11/704
[7] Nobuoka, D., et al. (2013). Peptide vaccines for hepatocellular carcinoma. World Journal of Gastroenterology, 19(21), 3194-3202. https://pmc.ncbi.nlm.nih.gov/articles/PMC3667940/
[8] Baretti, M., et al. (2025). A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma. Nature Medicine, 31(1), 100-109. https://www.nature.com/articles/s41591-025-03995-y
[9] Fibrolamellar Cancer Foundation. (n.d.). A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial. https://fibrofoundation.org/flc-research/a-therapeutic-peptide-vaccine-for-fibrolamellar-hepatocellular-carcinoma-a-phase-1-trial/
[10] Bal, C., et al. (2024). A Novel Peptide Binder to Glypican-3 Demonstrates High Affinity and Specificity for Hepatocellular Carcinoma. Journal of Nuclear Medicine, 65(Supplement 2), 241439. https://jnm.snmjournals.org/content/65/supplement_2/241439
[11] Charneau, J., et al. (2021). Peptide-Based Vaccines for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 8, 291-305. https://www.tandfonline.com/doi/full/10.2147/JHC.S291558
[12] Yin, H., et al. (2023). Hybrid peptide NTP-217 triggers ROS-mediated rapid apoptosis in liver cancer cells. Journal of Experimental & Clinical Cancer Research, 42(1), 21. https://pmc.ncbi.nlm.nih.gov/articles/PMC9881410/
[13] Hussein, A. A. A., et al. (2025). Identification and exploration of anticancer activity of novel peptides targeting FGF19–FGFR4 pathway in hepatocellular carcinoma. Bioorganic & Medicinal Chemistry Letters, 74, 129000. https://www.sciencedirect.com/science/article/pii/S2214750025000332
[14] Wei, L. H., et al. (2021). Anticancer property of Hemp Bioactive Peptides in Hep3B human liver cancer cells. Food Science & Nutrition, 9(11), 6066-6075. https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.1976
[15] Zhang, Y., et al. (2019). Antitumor effects of Tv1 venom peptide in liver cancer. bioRxiv, 518340. https://www.biorxiv.org/content/10.1101/518340v2.full-text